X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ORCHID PHARMA LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ORCHID PHARMA LTD DISHMAN PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 25.1 -0.5 - View Chart
P/BV x 3.3 0.4 918.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ORCHID PHARMA LTD
Sep-13
DISHMAN PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs374194 193.0%   
Low Rs12935 368.3%   
Sales per share (Unadj.) Rs197.8276.5 71.5%  
Earnings per share (Unadj.) Rs21.2-79.2 -26.8%  
Cash flow per share (Unadj.) Rs34.7-43.5 -79.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.953.9 333.5%  
Shares outstanding (eoy) m80.6970.45 114.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.30.4 307.2%   
Avg P/E ratio x11.9-1.4 -820.9%  
P/CF ratio (eoy) x7.2-2.6 -275.0%  
Price / Book Value ratio x1.42.1 65.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3068,067 251.7%   
No. of employees `0000.82.8 29.6%   
Total wages/salary Rs m5,3552,527 211.9%   
Avg. sales/employee Rs Th19,252.76,956.1 276.8%   
Avg. wages/employee Rs Th6,459.5902.5 715.7%   
Avg. net profit/employee Rs Th2,064.1-1,993.0 -103.6%   
INCOME DATA
Net Sales Rs m15,96119,477 81.9%  
Other income Rs m265407 65.2%   
Total revenues Rs m16,22619,884 81.6%   
Gross profit Rs m4,1031,103 372.1%  
Depreciation Rs m1,0912,519 43.3%   
Interest Rs m9445,227 18.1%   
Profit before tax Rs m2,334-6,236 -37.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m624-125 -498.1%   
Profit after tax Rs m1,711-5,580 -30.7%  
Gross profit margin %25.75.7 454.1%  
Effective tax rate %26.72.0 1,331.1%   
Net profit margin %10.7-28.7 -37.4%  
BALANCE SHEET DATA
Current assets Rs m11,01811,014 100.0%   
Current liabilities Rs m9,51732,060 29.7%   
Net working cap to sales %9.4-108.1 -8.7%  
Current ratio x1.20.3 337.0%  
Inventory Days Days11095 116.5%  
Debtors Days Days3534 103.8%  
Net fixed assets Rs m16,30429,440 55.4%   
Share capital Rs m161705 22.9%   
"Free" reserves Rs m12,9072,043 631.9%   
Net worth Rs m14,5163,800 382.0%   
Long term debt Rs m4,1899,018 46.5%   
Total assets Rs m29,80546,510 64.1%  
Interest coverage x3.5-0.2 -1,797.3%   
Debt to equity ratio x0.32.4 12.2%  
Sales to assets ratio x0.50.4 127.9%   
Return on assets %8.9-0.8 -1,172.2%  
Return on equity %11.8-146.9 -8.0%  
Return on capital %17.5-3.7 -469.4%  
Exports to sales %24.837.9 65.4%   
Imports to sales %3.722.6 16.5%   
Exports (fob) Rs m3,9567,378 53.6%   
Imports (cif) Rs m5964,406 13.5%   
Fx inflow Rs m4,9527,513 65.9%   
Fx outflow Rs m6975,649 12.3%   
Net fx Rs m4,2551,865 228.2%   
CASH FLOW
From Operations Rs m2,7861,682 165.7%  
From Investments Rs m-1,529-9,860 15.5%  
From Financial Activity Rs m-9416,644 -14.2%  
Net Cashflow Rs m316-1,535 -20.6%  

Share Holding

Indian Promoters % 61.4 32.3 190.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.6 80.4%  
FIIs % 12.7 3.3 384.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 22.1 55.3 40.0%  
Shareholders   46,261 84,811 54.5%  
Pledged promoter(s) holding % 35.8 54.9 65.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  J.B.CHEMICALS  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - NOVARTIS COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS